share_log

九洲药业(603456.SH):盐酸多巴胺注射液获得药品注册证书

Zhejiang Jiuzhou Pharmaceutical (603456.SH): Dopamine Hydrochloride Injection obtained the pharmaceutical registration certificate.

Gelonghui Finance ·  Oct 31 03:43

Gelonghui, October 31st 丨 Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its holding subsidiary, Nanjing Kangchuanji Medical Technology Co., Ltd. (referred to as 'Kang Chuanji Medical'), has received the 'Drug Registration Certificate' for Dopamine Hydrochloride Injection issued by the National Medical Products Administration (Acceptance Number: CYHS2301483). Dopamine Hydrochloride Injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin septicemia, heart surgery, renal failure, and congestive heart failure; especially for shock with oliguria and normal or low peripheral vascular resistance that cannot be corrected after volume supplementation. It was developed by Hospira Pharmaceuticals and was first launched in the USA in 1974.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment